John Patrick Shannon Jr is Director of Xeris Biopharma Holdings, Inc.. Currently has a direct ownership of 2.11 Million shares of XERS, which is worth approximately $7.17 Million. The most recent transaction as insider was on Jan 03, 2025, when has been sold 39,443 shares (Common Stock) at a price of $3.61 per share, resulting in proceeds of $142,389. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 2.11M
12.85% 3M change
7.56% 12M change
Total Value Held $7.17 Million

John Patrick Shannon Jr Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 03 2025
SELL
Payment of exercise price or tax liability
$142,389 $3.61 p/Share
39,443 Reduced 1.84%
2,108,618 Common Stock
Aug 01 2024
BUY
Grant, award, or other acquisition
-
250,000 Added 9.36%
2,419,612 Common Stock
Jan 31 2024
SELL
Payment of exercise price or tax liability
$272,445 $2.46 p/Share
110,750 Reduced 4.9%
2,148,061 Common Stock
Jan 31 2024
BUY
Grant, award, or other acquisition
-
750,000 Added 25.79%
2,158,575 Common Stock
Jan 29 2024
SELL
Payment of exercise price or tax liability
$58,919 $2.66 p/Share
22,150 Reduced 0.97%
2,258,811 Common Stock
Jan 03 2024
SELL
Payment of exercise price or tax liability
$91,468 $2.24 p/Share
40,834 Reduced 1.76%
2,280,961 Common Stock
Nov 17 2023
BUY
Open market or private purchase
$50,461 $1.64 p/Share
30,769 Added 2.14%
1,408,575 Common Stock
Jan 31 2023
SELL
Payment of exercise price or tax liability
$12,251 $1.24 p/Share
9,880 Reduced 0.42%
2,321,795 Common Stock
Jan 31 2023
BUY
Grant, award, or other acquisition
-
750,000 Added 35.25%
1,377,806 Common Stock
Jan 29 2023
SELL
Payment of exercise price or tax liability
$29,501 $1.26 p/Share
23,414 Reduced 0.99%
2,331,675 Common Stock
Jan 03 2023
SELL
Payment of exercise price or tax liability
$46,294 $1.12 p/Share
41,334 Reduced 1.72%
2,355,089 Common Stock
Jan 31 2022
SELL
Payment of exercise price or tax liability
$15,818 $2.11 p/Share
7,497 Reduced 0.31%
2,396,423 Common Stock
Jan 29 2022
SELL
Payment of exercise price or tax liability
$33,110 $2.11 p/Share
15,692 Reduced 0.65%
2,403,920 Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
250,000 Added 28.77%
618,910 Common Stock
Nov 12 2021
BUY
Open market or private purchase
$126,000 $2.1 p/Share
60,000 Added 14.16%
363,829 Common Stock
Nov 11 2021
BUY
Open market or private purchase
$83,600 $2.09 p/Share
40,000 Added 11.63%
303,829 Common Stock
Oct 05 2021
BUY
Grant, award, or other acquisition
-
263,829 Added 50.0%
263,829 Common Stock

Also insider at

XERS
XERIS PHARMACEUTICALS INC Healthcare
JPS

John Patrick Shannon Jr

Director
Chicago, IL

Track Institutional and Insider Activities on XERS

Follow Xeris Biopharma Holdings, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells XERS shares.

Notify only if

Insider Trading

Get notified when an Xeris Biopharma Holdings, Inc. insider buys or sells XERS shares.

Notify only if

News

Receive news related to Xeris Biopharma Holdings, Inc.

Track Activities on XERS